The cystic fibrosis lung microenvironment alters antibiotic activity: causes and effects Source: Eur Respir Rev, 30 (161) 210055; 10.1183/16000617.0055-2021 Year: 2021
The matrix-fibroblast interplay contributes to HIF-1 alpha pathway activation: a possible therapeutic target in idiopathic pulmonary fibrosis (IPF) Source: Virtual Congress 2020 – Elucidating the mechanisms underlying lung repair and exploring therapeutic strategies in vitro Year: 2020
ELMOD2, a candidate gene for idiopathic pulmonary fibrosis, regulates antiviral responses Source: Annual Congress 2010 - Lung cell biology and immunology Year: 2010
CHIT1 is a novel therapeutic target in idiopathic pulmonary fibrosis (IPF): anti-fibrotic efficacy of OATD-01, a potent and selective chitinase inhibitor in the mouse model of pulmonary fibrosis Source: International Congress 2018 – Progress in basic and translational research on idiopathic interstitial pneumonias Year: 2018
Low apoptosis rate as a reason of local immune cell accumulation in interstitial lung diseases (ILD). The role of cytokine network Source: Eur Respir J 2006; 28: Suppl. 50, 826s Year: 2006
Latent TGF-ß binding protein 4 is an important factor that influences anti-inflammatory and cell-protective responses in the pathogenesis of pulmonary emphysema Source: Virtual Congress 2020 – Respiratory homeostasis and structural changes in disease Year: 2020
Resistance of BAL immune cells to apoptosis in interstitial lung diseases (ILD) with high local tumor necrosis factor-α (TNFα) levels as a possible consequence of common TNF receptor type 2 expression Source: Annual Congress 2008 - Role of bronchoalveolar lavage in studying the pathophysiology of interstitial lung disease Year: 2008
Possible mechanisms of action of azithromycin in cystic fibrosis Source: Annual Congress 2005 - Cystic fibrosis lung disease: pieces of the puzzle Year: 2005
c-Met expression induction in immune cells modulates pulmonary fibrosis progression Source: Virtual Congress 2020 – Physiological and cellular mechanisms affecting pulmonary pathologies Year: 2020
The future of targeted therapies for sarcoidosis Source: Annual Congress 2005 - Biological agents in the therapy of sarcoidosis Year: 2005
Nintedanib inhibits pro-fibrotic mediators from T cells with relevance to connective tissue disease-associated interstitial lung disease Source: International Congress 2017 – Lung fibrosis: basic science Year: 2017
PAH and inflammation: its role in pathogenesis - is it of value to modulate it? Source: Annual Congress 2005 - Challenges in the biological understanding of pulmonary arterial hypertension Year: 2005
N-acetyl cysteine inhibits IL-17-induced IL-8 production from human airway smooth muscle cells - a possible role for anti-oxidant treatment in chronic lung rejection? Source: Eur Respir J 2003; 22: Suppl. 45, 202s Year: 2003
Dysregulation of the expression and activity of antimicrobial peptides in COPD and cystic fibrosis Source: International Congress 2018 – Antimicrobial host defence and innate immunity in the lung Year: 2018
Inhibitory effect of statins on fibrogenic mediator production from lung cells Source: Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities Year: 2012
Th17 cytokines: novel potential therapeutic targets for COPD pathogenesis and exacerbations Source: Eur Respir J, 50 (4) 1602434; 10.1183/13993003.02434-2016 Year: 2017
PBI-compound, a novel first-in-class anti-inflammatory/fibrotic compound, reduces bleomycin-induced pulmonary fibrosis by inhibition of multiple pro-inflammatory/fibrotic key mediators Source: Annual Congress 2013 –Cell signalling and inflammation: what's new in 2013? Year: 2013
Modified sensitivity of alveolar cells to TRAIL-mediated apoptosis: a mechanism involved in emphysema pathogenesis with a potential impact on cancer therapy research Source: Annual Congress 2009 - Highlighting the epithelial cell in lung disease: from COPD to cancer to acute lung injury Year: 2009
PBI-compound, a novel first-in-class anti-fibrotic compound, inhibits CTGF and collagen production in murine and human fibroblasts, and reduces lung fibrosis in the bleomycin-induced lung fibrosis model Source: Annual Congress 2013 –Cell signalling and inflammation: what's new in 2013? Year: 2013